A Study of GWP42006 in People With Focal Seizures - Part B

Epilepsy Clinical Trial

Official title:

A Double Blind, Randomized, Placebo-controlled, Two-part Study to Investigate the Pharmacokinetics, Followed by Efficacy and Safety of GWP42006 as add-on Therapy in Patients With Inadequately Controlled Focal Seizures.

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02365610
• Other study ID #: GWEP1330 Part B
• Secondary ID: 2014-002594-11
• Status: Completed
• Phase: Phase 2
• Start date: March 2016
• Est. completion date: September 2017

Study information

• Verified date: December 2022
• Source: Jazz Pharmaceuticals
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

To investigate the potential antiepileptic effects of GWP42006 as add-on therapy in subjects with inadequately controlled focal seizures.

Description:

This is a double blind, randomized, placebo controlled, two-part study. Part B only will be described in this record.

Subjects who satisfy all inclusion and none of the exclusion criteria will enter a four-week baseline period, followed by a two-week dose escalation period (400 mg twice daily for one week, then 600 mg twice daily for one week), a six-week stable treatment period (800 mg twice daily) and a 12-day taper period. Subjects will be required to attend eight study visits. A follow-up phone call will take place four weeks after last dose.

Subjects will be randomized to receive in a 1:1 ratio, GWP42006 or placebo. Subjects will be required to record a daily diary with information about their seizures, investigational medicinal product (IMP) and concomitant antiepileptic drug (AED) administration.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 162
• Est. completion date: September 2017
• Est. primary completion date: July 2017
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 65 Years

Eligibility

For inclusion in Part B of the study patients must fulfil ALL of the following criteria:

• Male or female aged between 18 and 65 years, inclusive.

• Well-documented history of focal epilepsy, compatible electroencephalogram and clinical history.

• Documented computerized tomography / magnetic resonance imaging that shows no progressive neurologic abnormality.

• Has focal seizures despite prior treatment with at least two AEDs (whether as monotherapies or in combination).

• Currently treated with one to three AEDs.

• All medications or interventions for epilepsy (including ketogenic diet) must have been stable for one month prior to screening and the subject is willing to maintain a stable regimen throughout the study.

• Subject is willing to keep any factors expected to affect seizures stable (such as the level of alcohol consumption and smoking).

The patient may not enter Part B of the study if ANY of the following apply:

• Time of onset of focal epilepsy treatment is less than two years prior to enrolment.

• Patient has seizures that are not of focal onset.

• Patient only has focal seizures without impairment of consciousness or awareness and without an observable motor component (even if autonomic component is present).

• Episode(s) of status epilepticus during one year prior to screening.

• History of pseudo-seizures.

• Vagus Nerve Stimulation, Deep Brain Stimulation, Responsive Neurostimulator System or other epilepsy neurostimulation device have been implanted or activated less than one year prior to screening, and/or stimulation parameters have been stable for less than one month, and/or battery life of unit not anticipated to extend for duration of trial.

• Had epilepsy surgery within one year of screening.

• Subject has clinically significant unstable medical conditions other than epilepsy.

• Subject has an illness in the four weeks prior to screening or randomization, other than epilepsy, which in the opinion of the investigator would affect seizure frequency.

• Subject has significantly impaired hepatic function at Visit 1.

• Active suicidal plan/intent in the past six months, or a history of suicide attempt in the last two years, or more than one lifetime suicide attempt .

• Subject is currently using or has in the past used recreational or medicinal cannabis, or cannabinoid based medications within the three months prior to screening and is unwilling to abstain for the duration for the study.

• Subject has taken St John's Wort in the last two weeks and/or is unwilling to abstain throughout the study.

• Subject has consumed grapefruit or grapefruit juice three days prior to randomization and/or unwilling to abstain in the three days prior to Visits B2 and B7.

• Any known or suspected hypersensitivity to cannabinoids, sesame oil or any of the excipients of the IMP(s).

• Subjects who have received an IMP within the 12 weeks prior to the screening visit.

Related Conditions & MeSH terms

• Epilepsy
• Focal Seizures
• Seizures

Intervention

Drug:
• GWP42006

• Placebo Control

Locations

Country	Name	City	State
n/a

Sponsors (1)

Lead Sponsor	Collaborator
Jazz Pharmaceuticals

Countries where clinical trial is conducted

Czechia,  Hungary,  Italy,  Poland,  Spain,  United Kingdom, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Percentage change from baseline to the end of treatment in focal seizure frequency in subjects taking GWP42006 compared to placebo.		Day -28 to Day 57
Secondary	Number of subjects considered treatment responders.		Day -28 to Day 57
Secondary	Change from baseline in seizure subtypes frequency.		Day -28 to Day 57
Secondary	Change from baseline in composite seizure score.		Day -28 to Day 57
Secondary	Change from baseline in the number of focal seizure free days.		Day -28 to Day 57
Secondary	Change from baseline in the usage of rescue medication.		Day -28 to Day 57
Secondary	Subject Global Impression of Change (SGIC).		Day 57
Secondary	Physician Global Impression of Change (PGIC) at the end of treatment.		Day 57
Secondary	The incidence of adverse events as a measure of subject safety.		Day -28 to Day 96